Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Observational Study to Assess the Effectiveness and Safety of Lanreotide Autogel® in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Asia Region

NCT04696042 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT04696042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04696042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Observational Study to Assess the Effectiveness and Safety of Lanreotide Autogel® in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Asia Region
Lead sponsor
Asan Medical Center
Phase
Observational
Overall status
Completed
Start date
January 1, 2021
Completion date
January 27, 2025
Enrollment
71 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors